Trial Profile
Long-Term Study of B2036-PEG in Acromegaly - Long Term Study With B2036-PEG.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Mar 2017
Price :
$35
*
At a glance
- Drugs Pegvisomant (Primary)
- Indications Acromegaly
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 27 Mar 2017 New trial record